The latest price target for Editas Medicine (NASDAQ:EDIT) was reported by HC Wainwright & Co. on September 5, 2025. The analyst firm set a price target for $5.00 expecting EDIT to rise to within 12 months (a possible 93.65% upside). 14 analyst firms have reported ratings in the last year.

The latest analyst rating for Editas Medicine (NASDAQ:EDIT) was provided by HC Wainwright & Co., and Editas Medicine reiterated their buy rating.

The last upgrade for Editas Medicine Inc happened on August 8, 2024 when B of A Securities raised their price target to $15. B of A Securities previously had a neutral for Editas Medicine Inc.

The last downgrade for Editas Medicine Inc happened on December 16, 2024 when JP Morgan changed their price target from N/A to N/A for Editas Medicine Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Editas Medicine, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Editas Medicine was filed on September 5, 2025 so you should expect the next rating to be made available sometime around September 5, 2026.

While ratings are subjective and will change, the latest Editas Medicine (EDIT) rating was a reiterated with a price target of $5.00 to $5.00. The current price Editas Medicine (EDIT) is trading at is $2.58, which is out of the analyst’s predicted range.